News | November 17, 2011

Bain Capital to Acquire Physio-Control from Medtronic

November 18, 2011 – Medtronic and Bain Capital, a global private investment firm, today announced they have entered into a definitive agreement under which affiliates of Bain Capital will acquire Physio-Control. The stock of Physio-Control and related entities will be purchased for cash in a transaction valued at approximately $487 million.

Headquartered in Redmond, Wash., Physio-Control is a leader in professional emergency response products and services and has nearly 1,000 employees worldwide. Brian Webster, currently president, will continue to lead the company and will be named chief executive officer following completion of the transaction.

“We are pleased that Physio-Control has found another strong partner to prepare the company for the next stage of its growth,” said Omar Ishrak, chairman and chief executive officer of Medtronic. “For more than 55 years, Physio-Control has been developing technologies and designing devices that are legendary among emergency medical response professionals. With an impressive innovation pipeline and backing by Bain Capital, we believe Physio-Control will be well-positioned for growth and to continue its lifesaving mission to serve emergency responders, hospital care teams and their patients around the world.”

Physio-Control products, which include LifePak monitor / defibrillators, the Lucas 2 chest compression system, and the Lifenet system cloud-based data management tools, are used daily by emergency medical services (EMS) and hospital care teams worldwide. Physio-Control also provides a line of automated external defibrillators (AEDs) for lay responders’ use in workplace environments, airports, schools and communities in the case of a cardiac emergency.

“The dedicated people and innovative products of Physio-Control play a vital role in helping emergency responders and medical professionals save lives every day,” said Chris Gordon, a managing director at Bain Capital. “Physio-Control is an impressive market leader that has built an outstanding brand position and loyal customer base by providing high quality, mission-critical tools and superior service. We are extremely enthusiastic about the company’s growth prospects, and we look forward to working alongside Brian Webster and the whole Physio-Control team to support their strategic plans.”

The transaction is expected to close in the first quarter of calendar 2012, and is subject to certain regulatory and customary closing conditions.

Non-equity financing for the transaction is being provided by Citigroup Global Markets Inc. and RBC Capital Markets. Goldman Sachs is acting as financial advisor, and Skadden, Arps, Slate, Meagher & Flom LLP as legal advisor to Medtronic. Citigroup Global Markets Inc. and RBC Capital Markets are acting as financial advisors and Kirkland & Ellis as legal advisor to Bain Capital.

Medtronic expects to use a portion of the proceeds to offset any potential dilutive impact from this transaction to fiscal year 2012 non-GAAP earnings per share.

For more information: www.medtronic.com, www.baincapital.com

Related Content

wearable defibrillators prevent sudden cardiac death in pediatric patients
Feature | Sudden Cardiac Arrest| May 11, 2017
May 11, 2017 — A new study shows that the use of a wearable cardioverter defibrillator (WCD) is safe and effective in
Physio-Control Launches HeartSine samaritan PAD 360P Automated External Defibrillator in United States
Technology | Defibrillator Monitors| April 24, 2017
Physio-Control announced April 19 that the company’s HeartSine samaritan PAD 360P (SAM 360P) fully automatic external...
AEDs, automated external defibrillators, requirements, U.S. schools, JACC study
News | Defibrillator Monitors| March 30, 2017
Automated external defibrillators (AEDs) are associated with increased survival of sudden cardiac arrest when installed...
Philips, FDA, class I recall, HeartStart MRx Monitor/Defibrillator
News | Defibrillator Monitors| March 28, 2017
Philips and the U.S. Food and Drug Administration (FDA) announced the company has initiated a recall of its HeartStart...
Zoll, Hospital Wearable Defibrillator, HWD, FDA premarket approval
Technology | Defibrillator Monitors| March 10, 2017
Zoll Medical Corp. announced that the company’s Hospital Wearable Defibrillator (HWD) has been granted premarket...
LifePak, AED, sudden cardiac arrest, defibrillator, automatic external defibrillator

A Physio-Control LifePak CR Plus defibrillator shown in use during a hand-off to paramedics, who use larger, more sophisticated defibrillator-monitors (behind gloved paramedic).

Feature | Sudden Cardiac Arrest| September 28, 2016 | Allied Market Research
Automated external defibrillators (AED) are portable and lightweight devices used to deliver an electric shock throug
sudden cardiac arrest, out-of-hospital, comatose patients, University of Arizona study, wake up
News | Sudden Cardiac Arrest| July 13, 2016
Physicians may be drawing conclusions too soon about survival outcomes of patients who suffered a cardiac arrest...
Zoll LifeVest wearable defibrillator, WEARIT-II Registry results, CardioStim EuroPace 2016
News | Defibrillator Monitors| June 21, 2016
Zoll Medical Corp. announced that patients experience a high one-year survival rate following use of the LifeVest...
ResQCPR System, resuscitation devices, cardiac arrest, CPR, FDA
Technology | March 09, 2015
The U.S. Food and Drug Administration (FDA) approved the ResQCPR System, a system of two devices for first responders...
Overlay Init